Neuromyelitis Optica Spectrum Disorders Clinical Trial
Official title:
Treatment Response Among Chinese Patients With Acute Attack of Neuromyelitis Optica Spectrum Disorders: A Prospective, Multicenter Real-world Study
Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an
immune-mediated inflammatory demyelinating disease of the central nervous system mainly
involving optic nerve and spinal cord. It is clinically characterized by simultaneous or
sequential involvement of the optic nerve and spinal cord, presenting a progressive or
remission and relapse course, which can lead to paralysis and blindness.
The objective of this study is to provide evidence regarding treat effects and factors
related to prognosis which will help physicians better evaluable risk-benefit in NMOSD
management and improve patients' outcome.
Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an
immune-mediated inflammatory demyelinating disease of the central nervous system mainly
involving optic nerve and spinal cord. It is clinically characterized by simultaneous or
sequential involvement of the optic nerve and spinal cord, presenting a progressive or
remission and relapse course, which can lead to paralysis and blindness.
Globally, there is no solid data available for the diagnosis, treatment and prognosis of
patients with acute Neuromyelitis Optica Spectrum Disorders (NMOSD) attack, particularly very
rare data from prospective studies. This is a multicenter, prospective, real-world cohort
study in patients with acute NMOSD attack in China.
Baseline data for approximately 200 patients with acute NMOSD attack from approximately 4
centers will be collected. Patients with acute NMOSD attack (including first episodes and
relapses) whose expansile disability status score (EDSS ) ≥ 2 points at baseline will be
eligible to be further included in prospective study cohort for analysis of treatment effects
and prognosis.
The objective of this study is to provide evidence regarding treat effects and factors
related to prognosis which will help physicians better evaluable risk-benefit in NMOSD
management and improve patients' outcome.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02836327 -
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
|
N/A | |
| Recruiting |
NCT04146285 -
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
|
Phase 1 | |
| Not yet recruiting |
NCT06068829 -
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT04388072 -
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
|
||
| Completed |
NCT05871658 -
Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol
|
N/A | |
| Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
| Recruiting |
NCT06249438 -
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06413654 -
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03330418 -
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
|
Phase 3 | |
| Enrolling by invitation |
NCT02809079 -
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
|
Phase 4 | |
| Recruiting |
NCT02889965 -
The French Multiple Sclerosis Registry
|
N/A | |
| Completed |
NCT02850705 -
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
|
||
| Completed |
NCT04670770 -
An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06212245 -
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
|
Phase 4 | |
| Completed |
NCT03062579 -
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05730699 -
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
|
Phase 3 |